Alligator Bioscience AB (publ)

LSE:0RK9 Stock Report

Market Cap: SEK 399.5m

Alligator Bioscience Valuation

Is 0RK9 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0RK9 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 0RK9's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 0RK9's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0RK9?

Key metric: As 0RK9 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0RK9. This is calculated by dividing 0RK9's market cap by their current revenue.
What is 0RK9's PS Ratio?
PS Ratio14.4x
SalesSEK 27.77m
Market CapSEK 399.49m

Price to Sales Ratio vs Peers

How does 0RK9's PS Ratio compare to its peers?

The above table shows the PS ratio for 0RK9 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3.6x
AREC Arecor Therapeutics
5.8x35.2%UK£28.3m
TRX Tissue Regenix Group
1.6x15.1%UK£40.6m
PBX ProBiotix Health
4.8xn/aUK£10.3m
VRCI Verici Dx
2.4x78.8%UK£8.2m
0RK9 Alligator Bioscience
14.4x-8.0%SEK 399.5m

Price-To-Sales vs Peers: 0RK9 is expensive based on its Price-To-Sales Ratio (14.4x) compared to the peer average (3.6x).

Price to Sales Ratio vs Industry

How does 0RK9's PS Ratio compare vs other companies in the GB Biotechs Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
GNS Genus
1.7x3.5%US$1.41b
OXB Oxford Biomedica
4.5x21.0%US$554.49m
TRX Tissue Regenix Group
1.6x15.1%US$50.88m
PBX ProBiotix Health
4.8xn/aUS$12.88m
0RK9 14.4xIndustry Avg. 8.1xNo. of Companies7PS020406080100+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 0RK9 is expensive based on its Price-To-Sales Ratio (14.4x) compared to the European Biotechs industry average (8.1x).

Price to Sales Ratio vs Fair Ratio

What is 0RK9's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0RK9 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio14.4x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 0RK9's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0RK9 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 0.57
SEK 2.00
+253.4%
25.0%SEK 2.50SEK 1.50n/a2
Nov ’25SEK 0.82
SEK 2.10
+154.5%
20.6%SEK 2.50SEK 1.50n/a3
Oct ’25SEK 1.30
SEK 2.27
+74.6%
9.1%SEK 2.50SEK 2.00n/a3
Sep ’25n/a
SEK 2.23
0%
7.6%SEK 2.40SEK 2.00n/a3
Aug ’25SEK 1.42
SEK 2.23
+56.8%
7.6%SEK 2.40SEK 2.00n/a3
Jul ’25SEK 1.12
SEK 1.90
+69.6%
29.8%SEK 2.30SEK 1.10n/a3
Jun ’25n/a
SEK 1.90
0%
29.8%SEK 2.30SEK 1.10n/a3
May ’25n/a
SEK 2.30
0%
28.4%SEK 3.10SEK 1.50n/a3
Apr ’25n/a
SEK 2.30
0%
28.4%SEK 3.10SEK 1.50n/a3
Mar ’25SEK 1.12
SEK 2.30
+105.4%
28.4%SEK 3.10SEK 1.50n/a3
Feb ’25SEK 1.24
SEK 1.83
+47.6%
32.2%SEK 2.30SEK 1.00n/a3
Jan ’25n/a
SEK 1.83
0%
32.2%SEK 2.30SEK 1.00n/a3
Dec ’24n/a
SEK 1.83
0%
32.2%SEK 2.30SEK 1.00n/a3
Nov ’24SEK 0.39
SEK 1.83
+372.5%
32.2%SEK 2.30SEK 1.00SEK 0.823
Oct ’24n/a
SEK 1.90
0%
29.8%SEK 2.30SEK 1.10SEK 1.303
Sep ’24SEK 0.40
SEK 1.90
+379.2%
29.8%SEK 2.30SEK 1.10n/a3
Aug ’24SEK 0.39
SEK 1.90
+381.6%
29.8%SEK 2.30SEK 1.10SEK 1.423
Jul ’24SEK 0.47
SEK 2.33
+393.3%
33.3%SEK 3.30SEK 1.40SEK 1.123
Jun ’24SEK 0.52
SEK 4.60
+789.6%
50.0%SEK 6.90SEK 2.30n/a2
May ’24SEK 0.61
SEK 4.60
+654.1%
50.0%SEK 6.90SEK 2.30n/a2
Apr ’24n/a
SEK 4.60
0%
50.0%SEK 6.90SEK 2.30n/a2
Mar ’24SEK 1.45
SEK 4.40
+204.3%
43.2%SEK 6.90SEK 2.30SEK 1.123
Feb ’24n/a
SEK 3.97
0%
34.0%SEK 5.60SEK 2.30SEK 1.243
Jan ’24n/a
SEK 3.63
0%
39.1%SEK 5.60SEK 2.30n/a3
Dec ’23n/a
SEK 3.63
0%
39.1%SEK 5.60SEK 2.30n/a3
Nov ’23n/a
SEK 3.63
0%
39.1%SEK 5.60SEK 2.30SEK 0.393

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Laboratorios Farmaceuticos Rovi

€3.2b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€62.90

7D

1.0%

1Y

13.3%

hVIVO

UK£149.7m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.22

7D

-13.4%

1Y

17.3%

Regeneron Pharmaceuticals

US$79.4b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$748.39

7D

-1.6%

1Y

-6.1%